Transdermal oxybutynin

Drugs

Volumn 69, Issue 3, 2009, Pages 327-337

  Baldwin, Claudine M ^a,b   Keating, Gillian M ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DARIFENACIN; DRUG METABOLITE; GASTROINTESTINAL AGENT; MUSCARINIC RECEPTOR; N NOROXYBUTYNIN; OXYBUTYNIN; PLACEBO; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE; UNCLASSIFIED DRUG;

APPLICATION SITE DERMATITIS; APPLICATION SITE ERYTHEMA; APPLICATION SITE IRRITATION; APPLICATION SITE PRURITUS; APPLICATION SITE RASH; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; COST CONTROL; COST MINIMIZATION ANALYSIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG INDICATION; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSURIA; HUMAN; NAUSEA; OVERACTIVE BLADDER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; SOMNOLENCE; TRANSDERMAL PATCH; URINARY FREQUENCY; VISUAL DISORDER; XEROSTOMIA;

ADMINISTRATION, CUTANEOUS; HUMANS; MANDELIC ACIDS; MUSCARINIC ANTAGONISTS; URINARY BLADDER, OVERACTIVE;

EID: 62149085144     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200969030-00008     Document Type: Review

References (36)

1. International Continence Society. ICS factsheet 2: overactive bladder [online]. Available from URL: http://www.icsoffice.org/ASPNET-Membership/ Membership/Documents/Documents.aspx?FolderID=30 [Accessed 2009 Feb 25]
2. Diokno AC. Medicalmanagement of urinary incontinence. Gastroenterology 2004; 126 (1): S77-81
3. AHCPR. Managing acute and chronic urinary incontinence. Am Fam Physician 1996 Oct; 54: 1661-72
4. UCB. The first European transdermal oxybutynin treatment for overactive bladder, Kentera® [media release]. 2005
5. Starkman JS, Dmochowski RR. Management of overactive bladder with transdermal oxybutynin. Rev Urol 2006; 8 (3): 93-103
6. European Medicines Agency. European public assessment report (scientific discussion): Kentera [online]. Available from URL: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/ Kentera/176804en6.pdf [Accessed 2009 Feb 25]
7. Sand PK. Subjective measures of efficacy: quality of life, patient satisfaction and patient-oriented goals - the search for value. Eur Urol Suppl 2007; 6 (5): 438-43
8. Watson Pharmaceuticals Inc. Oxytrol (oxybutynin transdermal system) patch: US prescribing information [online]. Available from URL: http://pi.watson.com/data-stream.asp?product-group=1295&p=pi&language=E [Accessed 2009 Feb 25]
9. European Medicines Agency. Summary of product characteristics: Kentera 3.9mg/24 hours, transdermal patch [online]. Available from URL: http://www.emea.europa.eu/humandocs/ PDFs/EPAR/Kentera/H-532-PI-en.pdf [Accessed 2009 Feb 25]
10. Yarker YE, Goa KL, Fitton A. Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995; 6 (3): 243-62
11. Comer AM, Goa KL. Extended-release oxybutynin. Drugs Aging 2000 Feb; 16: 149-55
12. Bang LM, Easthope SE, Perry CM. Transdermal oxybutynin: for overactive bladder. Drugs Aging 2003; 20 (11): 857-64
13. Waldeck K, Larsson B, Andersson KE. Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol 1997 Mar; 157 (3): 1093-7
14. Oki T, Toma-Okura A, Yamada S. Advantages for transdermal over oral oxybutynin to treat overactive bladder: muscarinic receptor binding, plasma drug concentration, and salivary secretion. J Pharmacol Exp Ther 2006 Mar; 316 (3): 1137-45
15. Davila GW, Daugherty CA, Sanders SW. A short-term,multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001 Jul; 166 (1): 140-5
16. Zobrist RH, Schmid B, Feick A, et al. Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers. Pharm Res 2001 Jul; 18 (7): 1029-34
17. Zobrist RH, Quan D, Thomas HM, et al. Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system. Pharm Res 2003 Jan; 20 (1): 103-9
18. Hill LA, Caramelli KE, Thomas HM. Comparative bioavailability and metabolism of transdermal oxybutynin (OXY-TDS) applied to the buttocks and back [abstract no. 252]. Annual Meeting of the American College of Clinical Pharmacy; 2007 Oct 14-17; Denver (CO)
19. Appell RA, Chancellor MB, Zobrist RH, et al. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc 2003 Jun; 78 (6): 696-702
20. Dmochowski RR, Sand PK, Zinner NR, et al. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge andmixed urinary incontinence. Urology 2003; 62 (2): 237-42
21. Dmochowski RR, Davila GW, Zinner NR, et al. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002 Aug; 168 (2): 580-6
22. Sand P, Zinner N, Newman D, et al. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU Int 2007 Apr; 99 (4): 836-44
23. Dmochowski RR, Sanders SW, Appell RA, et al. Bladder-health diaries: an assessment of 3-day vs 7-day entries. BJU Int 2005; 96: 1049-54
24. Sand PK, Goldberg RP, Dmochowski RR, et al. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. Am J Obstet Gynecol 2006 Dec; 195 (6): 1730-5
25. Staskin DR, Rosenberg MT, Dahl NV, et al. Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions. Int J Clin Pract 2008 Jan; 62 (1): 27-38
26. Pizzi LT, Talati A, Gemmen E, et al. Impact of transdermal oxybutynin on work productivity in patients with overactive bladder: results from the MATRIX study. Pharmacoeconomics. In press
27. Davila GW, Sand PK, Gonick CW, et al. Impact of transdermal oxybutynin on nocturia and related symptoms in overactive bladder: results from MATRIX study. Obstet Gynecol 2006 Apr; 107 Suppl.: 76
28. Sand PK, Lucente VR, Parker RL, et al. Impact of transdermal oxybutynin on depression symptoms in patients with overactive bladder: results of the MATRIX study. Obstet Gynecol 2006 Apr; 107 Suppl.: 76
29. Staskin DR, Nitti VW, Dmochowski RR. Quality of life following treatment with transdermal oxybutynin: the effects of prior therapy [abstract no. 84]. Neurourol Urodyn 2006 Jan 1; 25 (6): 611-2
30. Sand PK, Dahl NV. Satisfaction with transdermal oxybutynin treatment for overactive bladder in women younger and those older than 45 years. Obstet Gynecol 2008 Apr; 111 (4 Suppl.): 111S
31. Hamad RA, Dmochowski RR, McIlwain M, et al. MATRIX results: does quality of life differ in overactive bladder patients older and younger than 75 years treated with transdermal oxybutynin? J Am Geriatr Soc 2006 Apr 1; 54 Suppl.: 22
32. Davila WG, Dahl NV. Transdermal oxybutynin treatment for overactive bladder in women receiving estrogen therapy. Obstet Gynecol 2008 Apr; 111 (4 Suppl.): 112S
33. Sand P, McIlwain M. Transdermal oxybutynin for overactive bladder: satisfaction and perceived effectiveness [abstract no. 89]. 38th Annual Meeting of the International Continence Society; 2008 Oct 20-24; Cairo
34. Dmochowski RR, Nitti V, Staskin D, et al. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol 2005 Sep; 23 (4): 263-70
35. Ko Y, Malone DC, Armstrong EP. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder. Pharmacotherapy 2006 Dec; 26 (12): 1694-702
36. Sverre JM, Holm LB, Kristensen FKO. A cost-minimization analysis of oxybutynin (transdermal delivery system) compared to tolterodine (tablets) in the treatment of patients with urge or mixed urinary incontinence in Sweden. Value Health 2007 Dec; 10: 315. Plus poster presented at ISPOR 10th Annual European Congress; 2007 Oct 20-23; Dublin.